Shenzhen Everwin Precision Technology (300115.SZ) plans to launch the sixth phase of the employee stock ownership plan with a fundraising limit of 59.995 million yuan.
Changying Precision (300115.SZ) disclosed the sixth phase of employee stock ownership plan (draft), the total raised funds for the employee stock ownership plan is capped at 59.995 million RMB. The source of the employee stock ownership plan shares is the company's repurchased RMB ordinary shares purchased from the company's repurchase special security account, specifically 2.918 million shares of company stock repurchased by the company between October 14, 2025, and November 15, 2025, at a price of 20.56 RMB per share.
Shenzhen Everwin Precision Technology (300115.SZ) disclosed the sixth phase employee stock ownership plan (draft), with a total funding limit of 59.995 million yuan. The source of stocks for the employee stock ownership plan is the company's repurchased RMB common shares through the repurchase special securities account, namely 2.918 million shares of company stock repurchased by the company from October 14, 2025 to November 15, 2025, at a price of 20.56 yuan per share.
The duration of this employee stock ownership plan is 36 months, starting from the date of the transfer of the last batch of stocks to the employee stock ownership plan after the announcement of the listed company.
Related Articles

CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.
CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.






